Improving quality of life in patients with non-small cell lung cancer: Research experience with gemcitabine

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 1, 1997, Pages S8-

  Thatcher, N ^a   Hopwood, P ^b   Anderson, H ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Clinical trials; Gemcitabine; Non small cell lung cancer; Quality of life; Review

Indexed keywords

GEMCITABINE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; META ANALYSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030931222     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(96)00336-x     Document Type: Conference Paper

References (33)

1. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality of life in cancer clinical trials. Rec Res Cancer Res 1988, 111, 231-249.
2. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11, 570-579.
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-375.
4. Bergman B, Aaronson NK, Ahmedxia B, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994, 30A, 635-642.
5. De Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom checklist. Br J Cancer 1990, 62, 1034-1038.
6. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose and method of measurement. Cancer Invest 1993, 11, 327-336.
7. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: The Functional Living Index - Cancer: development and validation. J Clin Oncol 1984, 2, 472-483.
8. Hopwood P. Quality of life assessment in non-small cell lung cancer: are theory and practice significantly different? Semin Oncol 1996, 32A, 243-248.
9. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 1995, 71, 633-636.
10. Bunn PA. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol 1994, 21 (suppl 6), 49-59.
11. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and the general public. Br Med J 1990, 300, 1458-1460.
12. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995, 311, 899-909.
13. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12 (8), 1535-1540.
14. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12 (8), 1821-1826.
15. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJM. Activity of gemcitabine in patients with non-small-cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996, 32A, 243-248.
16. Fossella FV, Lippman SM, Tarassoff P, et al. Phase I/II study of gemcitabine, an active agent for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995, 14, 371 (abstract No. 1144).
17. Tonato M, Mosconi A-M, Martin C. Safety profile of gemcitabine. Anti-Cancer Drugs 1995, 6 (suppl 6), 27-32.
18. Cullen MH. The MIC regimen in non-small cell lung cancer. Lung Cancer 1993, (suppl 2), 81-89.
19. Medical Research Council by its Lung Cancer Working party. Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991, 63, 265-270.
20. Wolf J, Spear P, Yesner R, et al. Nitrogen mustard and the steroid hormones in the treatment of inoperable bronchogenic carcinoma. Am J Med 1960, 29, 1008-1016.
21. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969, 46, 516-525.
22. Durrant KR, Berry RJ, Ellis F, et al. Comparison of treatment policies in inoperable bronchial carcinoma. Lancet 1971, 1, 715-719.
23. Laing AH, Berry RJ, Newman CR. Treatment of inoperable carcinoma of bronchus. Lancet 1975, 2, 1161-1164.
24. Cormier Y, Bergeron D, La Forge J, et al. Benefits of polychemotherapy in advanced non small cell bronchogenic carcinoma. Cancer 1982, 50, 845-849.
25. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer -report of a Canadian multicenter randomised trial. J Clin Oncol 1988, 6, 633-641.
26. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non small cell lung cancer. Does chemotherapy make a difference? Cancer 1989, 63, 1271-1278.
27. Woods RL, Williams CJ, Levi J, et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990, 61, 608-611.
28. Buccheri G, Ferrigho D, Rosso A, et al. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990, 6, 87-98.
29. Kaasa S, Lund E, Thorud E, et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non small cell lung cancer. Cancer 1991, 67, 2443-2447.
30. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive cancer in advanced non small cell lung cancer. J Clin Oncol 1991, 9, 1453-1461.
31. Quoix E, Dietemann A, Charbonneau J, et al. La chimioterapie comportant due cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Resultats d'une etude randomisee. Bull Cancer 1991, 78, 341-346.
32. Leung WT, Shiu WCT, Pang JCK, et al. Combined chemotherapy and radiotherapy versus best supportive cancer in the treatment of inoperable non small cell lung cancer. Oncology 1992, 49, 321-326.
33. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclo-phosphamide-mitomycin combination Chemotherapie with supportive cancer versus supportive cancer alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993, 85, 794-800.